IMU Stock Overview
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
ImmunoGen, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$28.74 |
| 52 Week High | US$29.00 |
| 52 Week Low | US$3.36 |
| Beta | 1.17 |
| 1 Month Change | 7.04% |
| 3 Month Change | 110.09% |
| 1 Year Change | 615.55% |
| 3 Year Change | 226.59% |
| 5 Year Change | 482.96% |
| Change since IPO | 1,149.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| IMU | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 6.8% | -4.3% | -2.5% |
| 1Y | 615.5% | -19.4% | -0.4% |
Return vs Industry: IMU exceeded the German Biotechs industry which returned -21% over the past year.
Return vs Market: IMU exceeded the German Market which returned -1.4% over the past year.
Price Volatility
| IMU volatility | |
|---|---|
| IMU Average Weekly Movement | 25.0% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: IMU's share price has been volatile over the past 3 months.
Volatility Over Time: IMU's weekly volatility (25%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 277 | Mark Enyedy | www.immunogen.com |
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate.
ImmunoGen, Inc. Fundamentals Summary
| IMU fundamental statistics | |
|---|---|
| Market cap | €7.76b |
| Earnings (TTM) | -€68.27m |
| Revenue (TTM) | €267.08m |
29.1x
P/S Ratio-113.7x
P/E RatioIs IMU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMU income statement (TTM) | |
|---|---|
| Revenue | US$287.61m |
| Cost of Revenue | US$211.62m |
| Gross Profit | US$76.00m |
| Other Expenses | US$149.52m |
| Earnings | -US$73.52m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 26.42% |
| Net Profit Margin | -25.56% |
| Debt/Equity Ratio | 12.8% |
How did IMU perform over the long term?
See historical performance and comparison